ferent cytokines at saturated concentrations and then incubated for up to 24 hours. Lysates and supernatants were collected and intracellular and extracellular signals were measured using a high throughput method of bead-based fluorescent readings (Luminex xMAP assay, Austin, TX). For each treatment 18 different phosphoprotein signals was measured including p-AKT, p-MEK, p-ERK, p-p38, p-IκB at 10 and 25 minutes post-stimuli. At 24 hours supernatants were collected and approximately 60 different proteins including cytokines and metalloproteinases (MMPs) were measured. Data were normalized and plotted using custom software based on the DataRail toolbox and subsequent analysis was performed using PLSR, PCA, and clustering algorithms that have developed previously. Results: IL1α, IL1β, and TNFα showed a significant release of several procatabolic proteins such as MMP1 and MMP13 but also pro-inflammatory cytokines such as GROα, MCP1, MIP1α, and MIP1β. Interestingly, clustering analysis revealed a number of TLR stimuli such as LPS and POLY I:C to behave on a similar manner. Closer look into the phosphoprotein activity of those proteins showed they act via the NFκB and possibly via the p38 pathways. Follow up experiment using selective p38 and IκB inhibitors proved the pro-catabolic response of chondrocytes triggered by TLR agonists is NFκB dependant. Conclusions: "Functional" screens based on intracellular and extracellular activities revealed that chondrocytes respond to a large number of stimuli that has not been well characterized. TLR stimuli showed a behavior similar to IL1α and TNFα. Upon TLR stimuli, chondrocytes shows an "immune-cell" phenotype by releasing MMPs and several pro-catabolic and inflammaroty cytokines via the NFκB pathway.
Purpose: To examine comorbidities, pain-related pharmacotherapy, health service use and direct medical costs of patients with osteoarthritis (OA) in clinical practice. Methods: This study was a retrospective cohort analysis based on a medical and pharmacy claims database. Using the PharMetrics ® Database, OA patients (International Classification of Diseases, Ninth Revision, Clinical Modification codes 715.XX) were identified and matched (age, gender, and region) with a Control group of individuals without OA. Clinical comorbidities, pain-related pharmacotherapy, and health service use/direct medical costs (pharmacy, outpatient, inpatient, total) were then examined during the calendar year 2008. Results: A total of 112,951 patients with OA satisfied all the study entry criteria and were matched to 112,951 Controls without OA (mean age: 56.9±9.5 years; 62% female). Relative to Controls, OA patients were significantly more likely (p<0.0001) to have various comorbidities, including musculoskeletal (84.3% versus 37.1%) and neuropathic pain (22.0% versus 6.1%) conditions, depression (12.4% versus 6.4%), anxiety (6.6% versus 3.5%), and sleep disorders (11.9% versus 4.2%). OA patients were significantly more likely (p<0.0001) to receive pain-related medications, including opioids (40.7% versus 17.1%), NSAIDs (37.1% versus 11.5%), tramadol (9.8% versus 1.8), and prescription acetaminophen (1.3% versus 0.8%) relative to Controls. OA patients were also significantly more likely (p<0.0001) to be prescribed "adjunctive" medications for treating conditions associated with pain including depression, anxiety, and insomnia (antidepressants, 21.5% versus 15.7%; benzodiazepines, 13.6% versus 9.1%; sedative/hypnotics, 9.6% versus 5.3%). Use of healthcare resources including hospitalizations, emergency room, physician office, and outpatient visits was significantly higher (p<0.0001) among OA patients relative to Controls; a majority of OA patients (88% versus. 51% of Controls) had ≥4 physician office visits; OA patients averaged 22 outpatient visits (versus 9 in Controls); over 13% of OA patients underwent OA-related surgeries; and 34% received intra-articular injections during 2008. Relative to Controls, mean [SD] total direct medical costs during 2008 were more than two times higher among OA patients ($12,905 [$21,884] versus $5,099 [$13,855]; p < 0.001) and median costs were more than three times higher ($6,188 versus $1,879); p<0.0001.
Conclusions:
The payer burden associated with OA was substantial, evidenced by significantly greater use of pain-related and adjunctive medications and higher health service utilization and direct medical costs. The patient burden, characterized by the higher prevalence of various comorbidities was also substantial. Purpose: Erosive hand osteoarthritis (EOA) is considered a subset of hand osteoarthritis (OA) affecting mainly the interphalangeal (IP) joints. Because little is known about its etiology, we evaluated potential risk factors for the evolution of EOA. Methods: Hand radiographs of 236 hand OA patients (mean age 59 yrs, 83% women) participating in the Genetics, ARthrosis and Progression (GARP) study were obtained at baseline and after six years. Hand OA was defined by the ACR criteria for clinical hand OA or the presence of structural abnormalities (nodes/radiographic OA). Evolution in anatomical phase of IP joints according to the Verbruggen-Veys system was assessed by scoring paired radiographs in chronological order. In every IP joint the presence of self-reported pain and stiffness (using a diagram including all IP joints), the presence of pain on joint pressure and the presence of nodes was evaluated at baseline. In addition, osteophytes and joint space narrowing (JSN) were scored using the OARSI atlas. At the patient level, pain and functional limitations were assessed with the Australian/Canadian Osteoarthritis Hand Index (AUSCAN). Baseline HsCRP levels and innate cytokine production (interleukin (IL)-1β, IL-1β receptor antagonist, IL-10 and tumor necrosis factor-α) were included to reflect systemic inflammation and its predisposition. Risk factors for the evolution of non-EOA IP joints to EOA and for the evolution of active erosions to remodeling were assessed using Generalized Estimating Equations (GEE) to take into account intra-patient correlation. Results: At baseline and follow-up 203 (4.7%) and 315 (7.4%) respectively of the 4232 IP joints were classified as EOA. Non-EOA was present in 1487 (35%) at baseline and 1530 (36%) IP joints at follow-up. The remaining IP joints were classified as normal. Of the 1487 non-EOA IP joints at baseline 97 (6.5%) progressed to EOA. Clinical and radiographic risk factors for this evolution are shown in the table. Of the 91 IP joints with active erosions at baseline 69 (76%) became remodeled. The presence of self-reported pain was an independent risk factor for this ongoing erosive evolution (OR (95%CI) 3.52 (1.08, 11.46)). Systemic inflammation was not associated with either of the processes. Table 1 . Association between evolution of non-EOA to EOA and baseline characteristics OR (95% CI)* OR (95% CI)**
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